SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after announcing a deal with OpenAI, which includes stock warrants and designates AMD as a core compute partner. The community is discussing the potential impact of this partnership on AMD's market share and revenue, with some speculating on future price targets. Broader discussions involve the AI infrastructure race and comparisons to Nvidia's position in the market.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a potential partnership with Tesla, fueled by a recent video showcasing Archer's eVTOL aircraft alongside Tesla's Optimus robot. The community is actively discussing the possibility of Tesla integrating Archer's technology for autonomous air taxis and battery solutions. This buzz comes as Archer progresses towards regulatory approvals and expands into defense applications.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following the FDA's Breakthrough Therapy Designation for its treatment of Sanfilippo syndrome type B. The community is discussing the potential for a short squeeze, fueled by the stock's low float and recent reverse split, while comparing it to other high-flying stocks and anticipating further upward momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending due to reports of an SEC probe into its data collection practices, leading to a sharp decline in its stock price. The community is debating whether this is a buying opportunity or a sign of deeper issues, with some pointing to past short-seller reports and inflated valuations. Despite the recent surge driven by AI optimism and S&P 500 inclusion, the stock's future is uncertain as investors assess the potential impact of the investigation.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is trending due to a significant after-hours drop following its earnings report, where the company reported a year-over-year revenue decrease and did not issue formal guidance. Community members are actively discussing the company's cash burn, inventory levels, and the lack of specific guidance, with some anticipating a potential offering. Despite the concerns, some bulls remain optimistic about the company's wafer-level testing technology and potential in the AI market.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending amid speculation around a potential new product announcement, with community chatter focusing on whether it will be a game-changing affordable Model Y or a collaboration in the autonomous vehicle space. Some traders are also discussing the company's valuation and growth prospects, while others are eyeing technical indicators to predict short-term price movements. The potential announcement also has some traders discussing potential implications for other EV or tech companies.

BlackRock Institutional Trust Company N.A. - iShares Gold Trust

iShares Gold Trust

IAU is trending as gold prices reach record highs, fueled by safe-haven demand amidst US government shutdown concerns and a weaker dollar. The community is actively discussing potential further upside, with some analysts predicting prices could climb significantly higher. Investors are monitoring factors like potential Fed rate cuts and geopolitical tensions as key drivers for continued growth.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the idea of tokenizing the legacy of Satoshi Nakamoto, viewing it as the 'Bitcoin of Memes' with unlimited potential. Community members express strong conviction, emphasizing the movement's timeless nature and the significance of owning a piece of crypto history. The conversation highlights the idea that 'We are all Satoshi', suggesting a broad appeal and a shared identity within the crypto space.

Rio Tinto Plc engages in the exploration, mining, and processing of mineral resources. It operates through the following business segments: Iron Ore, Aluminium, Copper, and Minerals. The Iron Ore segment supplies iron ore mining and salt and gypsum production. The Aluminium segment produces bauxite, alumina and primary aluminum. The Copper segment offers gold, silver, molybdenum and other by-products. The Minerals includes businesses with products such as uranium, borates, salt and titanium dioxide feedstock together with coal operations. The Other Operations segment covers the curtailed Gove alumina refinery and Rio Tinto Marine operations. The company was founded in 1873 and is headquartered in London, the United Kingdom.

Rio Tinto plc - ADR

Rio Tinto plc

Rio Tinto is trending due to potential growth in the lithium sector following reports of a partnership to develop lithium extraction technology in Chile and speculation around mergers and acquisitions. Community discussions are centered on the company's long-term value, dividend payouts, and copper projects. Some investors express frustration with the stock's price action while others view it as a buying opportunity, citing strong financials and potential benefits from a Trump presidency.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss the potential of deep-sea mining for critical minerals and the company's strong fundamentals. Community members are weighing the potential for government investment and comparing TMC to other companies in the sector. Some are also focused on technical analysis, noting a potential cup and handle formation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zymeworks Inc. (ZYME) on Tuesday announced its decision to discontinue clinical development of ZW171, designed to target certain cancers.ZW171 is designed to address cancers driven by Mesothelin, a cell-surface protein overexpressed in certain cancers, including gynecological, thoracic, and digestive system cancers. The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.At the time of writing, <a href="https://stocktwits.com/symbol/ZYME">ZYME stock</a> was down by over 17% in Tuesday’s pre-market session. On Stocktwits, retail sentiment around ZYME stock, however, rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:655/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_8_57_28_AM_png_feb9611316.webp" alt="ZYME's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="655" height="61"><figcaption>ZYME's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>After establishing a maximum tolerated dose in the early-stage trial, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-decision-discontinue-clinical-development">determined</a> that further dose escalation would be unlikely to support a benefit-risk profile consistent with the company’s intent to develop it as a standalone therapy.While ongoing participants in the trial will continue treatment at the discretion of their investigator, participants who have discontinued treatment will continue safety follow-up as per the study protocol, Zymeworks said.Zymeworks CEO Kenneth Galbraith said that the outcome is “disappointing” given the promising preclinical activity observed with ZW171.“We continue to advance our broader product pipeline, including the ongoing Phase 1 trial of ZW191 and the initiation of a Phase 1 study for ZW251 expected in 2025. We are also preparing an IND filing for ZW209, our DLL3-directed trispecific T cell engager, planned in the first half of 2026,” he added.&nbsp;ZYME stock is up by 1% this year and nearly 29% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/merck-investigational-drug-shows-reduction-in-cholestrol-in-late-stage-trial/chv6ol3Rdnp">Merck’s Investigational Drug Shows Reduction In Cholesterol In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update

The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.

Equity

The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.


Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

Shares of Zymeworks Inc. (ZYME) were in the spotlight on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-nmpa-approval-zanidatamab-china-adults">announced</a> that the National Medical Products Administration (NMPA) in China approved Zanidatamab, a bispecific antibody it developed, for the treatment of patients with a type of biliary tract cancer (BTC).The approval is for the treatment of patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer, a diverse group of cancers that affect the bile ducts and gallbladder.Zymeworks’ collaboration partner, BeOne Medicines (formerly BeiGene), obtained conditional approval under the terms of its license and collaboration agreement with Zymeworks in the region.The continued approval of the therapy for BTC will depend on confirmation of clinical benefit through ongoing confirmatory trials, the company said.The U.S. Food and Drug Administration (FDA) approved the therapy for BTC in November. &nbsp;The incidence rate of BTC is on the rise globally, particularly in Asia, the company said, while also noting that BTC accounts for approximately 3% of all digestive system tumors.Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of Zanidatamab as part of its agreement with BeOne Medicines.The company is also eligible to receive up to $144 million in additional development and commercial milestones as well as tiered royalties of up to 19.5% of net sales in BeOne Medicine’s territories.On Stocktwits, retail sentiment around ZYME stayed unmoved within the ‘bearish’ territory over the past 24 hours while message volume dipped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_7_14_43_AM_png_38718537d5.webp" alt="ZYME's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ZYME's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ZYME">ZYME stock</a> is down by 23% this year but up by about 35% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/scott-bessent-says-trump-xi-call-needed-as-talks-with-china-are-a-bit-stalled/ch0MqYuRbMH">Scott Bessent Says Trump-Xi Call Needed As Talks With China Are ‘A Bit Stalled’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines.

TD Cowen initiated coverage of Zymeworks with a ‘Buy’ rating, citing its antibody platforms and highlighting Ziihera (zanidatamab-hrii), a targeted therapy for biliary tract cancer, as a potential blockbuster.The research firm expects critical clinical data in the second half of 2025.TD Cowen anticipates Ziihera royalties will support Zymeworks' pipeline development throughout the next two years.&nbsp;Zymeworks shares closed up 5.2% at $12.43 on Tuesday, holding steady after-hours.In November 2024, the U.S. FDA granted accelerated approval for Ziihera to treat previously treated, unresectable, and metastatic HER2-positive biliary tract cancer (BTC).The approval was based on data from the HERIZON-BTC-01 trial, which showed a 52% objective response rate and a median duration of response of 14.9 months.It also resulted in a $25 million milestone payment to the company, which can achieve further payments up to $500 million from regulatory milestones.&nbsp;Additionally, the company has access to $862.5 million from commercial milestones, along with tiered royalties ranging between 10% and 20%.Jazz Pharmaceuticals markets Ziihera through an exclusive license agreement signed in late 2022 that gives them rights to zanidatamab throughout the U.S., Europe, Japan, and select global markets, except for certain Asia-Pacific regions licensed to BeiGene.&nbsp;Ziihera generated net sales of $2 million for Jazz Pharmaceuticals in the first quarter, while producing $0.2 million in royalties for Zymeworks.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.The stock has declined 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy

The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.33	--	--	N/A
Q2 '25	-$0.48	$0.03	106.22%	BEAT
Q1 '25	-$0.68	-$0.30	56.12%	BEAT
Q4 '24	-$0.10	-$0.31	-211.88%	MISSED
Q3 '24	-$0.40	-$0.39	1.71%	BEAT

ZYME
Zymeworks Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ZYME News

ZYME Zymeworks Inc